Previous 10 | Next 10 |
Cyclacel is a biotech company developing small molecule drugs for treating cancer and other diseases. CEO Spiro Rombotis joined us for a discussion about cancer resistance and clinical trials. Investor updates including recent study of oral Fadraciclib in patients with advanced tu...
BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate i...
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2021 Earnings Conference Call August 11, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and CMO Conference Call Participants Jonathan Aschoff - ROTH Capital Kumar R...
- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET - BERK...
BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results ...
Cyclacel Pharmaceuticals (CYCC) announces dosing of the first patient in its multi-cohort Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors. The Phase 1/2 registration-directed trial (CYC065-101) uses a streamlined design and will first determine the recommended Phase...
BERKELEY HEIGHTS, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company...
BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Lade...
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2021 Earnings Conference Call May 12, 2021, 04:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and CMO Conference Call Participants Jonathan Aschoff - ROTH Capital Kevin De...
Cyclacel Pharmaceuticals (CYCC): Q1 GAAP EPS of -$1.48 misses by $0.99.As of March 31, 2021, cash and cash equivalents totaled $47.8 million, compared to $33.4 million as of December 31, 2020.Press Release For further details see: Cyclacel Pharmaceuticals EPS misses by $0.99
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...